BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer

Mikata, Rintaro; Fukai, Kenichi; Imazeki, Fumio; Arai, Makoto; Yonemitsu, Yutaka; Zhang, Kaiyu; Nabeya, Yoshihiro; Ochiai, Takenori; Yokosuka, Osamu

doi:10.3892/or_00000814

Cited by 13 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mikata et al showed that BCL2L10, which belongs to the family of pro-apoptotic Bcl-2, is silenced by hypermethylation of the promoter. This study suggests that silencing BCL2L10 by methylation is a common feature in gastric cancer and may be involved in the early stages of gastric carcinogenesis (81). …”

Section: Epigenetic Changes Promote the Development Of Gastric Cancermentioning

confidence: 75%

Genetic Alterations in Gastric Cancer Associated with Helicobacter pylori Infection

et al. 2017

View full text Add to dashboard Cite

Gastric cancer is a world health problem and depicts the fourth leading mortality cause from malignancy in Mexico. Causation of gastric cancer is not only due to the combined effects of environmental factors and genetic variants. Recent molecular studies have transgressed a number of genes involved in gastric carcinogenesis. The aim of this review is to understand the recent basics of gene expression in the development of the process of gastric carcinogenesis. Genetic variants, polymorphisms, desoxyribonucleic acid methylation, and genes involved in mediating inflammation have been associated with the development of gastric carcinogenesis. Recently, these genes (interleukin 10, Il-17, mucin 1, β-catenin, CDX1, SMAD4, SERPINE1, hypoxia-inducible factor 1 subunit alpha, GSK3β, CDH17, matrix metalloproteinase 7, RUNX3, RASSF1A, TFF1, HAI-2, and COX-2) have been studied in association with oncogenic activation or inactivation of tumor suppressor genes. All these mechanisms have been investigated to elucidate the process of gastric carcinogenesis, as well as their potential use as biomarkers and/or molecular targets to treatment of disease.

show abstract

Section: Epigenetic Changes Promote the Development Of Gastric Cancermentioning

confidence: 75%

Genetic Alterations in Gastric Cancer Associated with Helicobacter pylori Infection

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Additionally, patients with this BCL2L10 polymorphism have a diminished risk of the development de novo MDS [ 74 ]. Third, epigenetic regulation of Bcl-B has great significance in tumorigenesis: Methylation of the gene could lead to silenced or reduced expression of this protein in HCC [ 66 ] and gastric cancer [ 65 , 75 , 76 ]. Finally, a decrease in level of one antiapoptotic protein can be compensated for by an increase in the level of another prosurvival partner, a phenomenon that has been proved in various in vitro and in vivo models.…”

Section: Discovery Structure and Protein–protein Interactionsmentioning

confidence: 99%

Bcl-B: an “unknown” protein of the Bcl-2 family

Pervushin,

Kopeina,

Zhivotovsky

2023

Biol Direct

View full text Add to dashboard Cite

Bcl-B is a poorly understood protein of the Bcl-2 family that is highly expressed in many healthy tissues and tumor types. Bcl-B is considered an antiapoptotic protein, but many reports have revealed its contradictory roles in different cancer types. In this mini-review, we elucidate the functions of Bcl-B in normal conditions and various pathologies, its regulation of programmed cell death, its oncogene/oncosuppressor activity in tumorigenesis, its impact on drug-acquired resistance, and possible approaches to inhibit Bcl-B.

show abstract

Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Lee

Kang

et al. 2018

Med Oncol

View full text Add to dashboard Cite

A good pathologic response to neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) is associated with a better prognosis. However, there is no effective method to predict CRT response in LARC patients. Therefore, this study used whole-exome sequencing (WES) to identify novel biomarker predicting CRT benefit in LARC. Two independent tumor tissue sets were used to evaluate the genetic differences between the good CRT response group (15 patients achieved a pathologic complete response (pCR)) and the poor CRT response group (15 patients with pathologic stage III). After applying WES to the discovery set of 30 patients, additional samples (n = 67) were genotyped for candidate variants using TaqMan or Sanger sequencing for validation. Overall, this study included a total of 97 LARC patients. In the discovery and validation set, there was no known genetic mutation to predict response between two groups, while five candidate variants (BCL2L10 rs2231292, DLC1 rs3816748, DNAH14 rs3105571, ITIH5 rs3824658, and RAET1L rs912565) were found to be significantly associated with pCR. In the dominant model, the GC/CC genotype of DLC1 rs3816748 (p = 0.032), AC/CC genotype of DNAH14 rs3105571 (p = 0.009), and TT genotype of RAET1 rs912565 (p < 0.0001) were associated with a higher pCR rate. In the recessive model, BCL2L10 rs2231292 (p = 0.036) and ITIH5 rs3824658 (p = 0.003) were significantly associated with pCR. In the co-dominant model, 4 candidate variants (DLC1 rs3816748, DNAH14 rs3105571, ITIH5 rs3824658, and RAET1L rs912565) were significantly correlated with pCR. However, none of the candidate variants was associated with relapse-free or overall survival. The present results suggest that genetic variations of the BCL2L10 rs2231292, DLC1 rs3816748, DNAH14 rs3105571, ITIH5 rs3824658, and RAET1L rs912565 genes can be used as biomarkers predicting the CRT response for patients with LARC.

show abstract

BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer

Cited by 13 publications

References 20 publications

Genetic Alterations in Gastric Cancer Associated with Helicobacter pylori Infection

Genetic Alterations in Gastric Cancer Associated with Helicobacter pylori Infection

Bcl-B: an “unknown” protein of the Bcl-2 family

Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Contact Info

Product

Resources

About